Femme et Homme
- | Pays :
- United States
- South Africa
- Bulgaria
- Les 8 autres...
- | Organes : -
- | Spécialités : -
Extrait
This study is being conducted to confirm the efficacy, safety, and immunogenicity of recombinant human C1 inhibitor (rhC1INH) at a dose of 50 U/kg when used for the treatment of acute angioedema attacks in Hereditary Angioedema (HAE) patients.
Critère d'inclusion
- hereditary angioedema